

# Alex G Ortega-Loayza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/13876/publications.pdf>

Version: 2024-02-01

113  
papers

1,960  
citations

304743

22  
h-index

315739

38  
g-index

115  
all docs

115  
docs citations

115  
times ranked

1747  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atypical Pyoderma Gangrenosum in the Setting of Venous and Arterial Insufficiency. International Journal of Lower Extremity Wounds, 2023, 22, 418-422.	1.1	2
2	Health-related domains of quality of life in pyoderma gangrenosum: A qualitative analysis. Journal of the American Academy of Dermatology, 2022, 86, 1382-1385.	1.2	11
3	Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels. Journal of Investigative Dermatology, 2022, 142, 235-239.e1.	0.7	10
4	Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression. Journal of Investigative Dermatology, 2022, 142, 1217-1220.e14.	0.7	18
5	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 2022, 238, 430-437.	2.1	4
6	Wound care dressings for pyoderma gangrenosum. Journal of the American Academy of Dermatology, 2022, 86, 458-460.	1.2	7
7	Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. JAMA Dermatology, 2022, 158, 176.	4.1	31
8	Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa. Journal of Clinical Medicine, 2022, 11, 670.	2.4	2
9	Hidden in plain sight: Considerations for an ulcer of the scalp. Head and Neck, 2022, , .	2.0	1
10	Calciphylaxis: Part I. Diagnosis and pathology. Journal of the American Academy of Dermatology, 2022, 86, 973-982.	1.2	11
11	Modified dose of guselkumab for treatment of pyoderma gangrenosum. JAAD Case Reports, 2022, 21, 38-42.	0.8	8
12	Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: A retrospective study. Journal of the American Academy of Dermatology, 2022, 87, 1130-1133.	1.2	4
13	Calciphylaxis: Treatment and outlookâ€”CME part II. Journal of the American Academy of Dermatology, 2022, 86, 985-992.	1.2	6
14	Pyoderma gangrenosum study pilot registry: The first step to a better understanding. Wound Repair and Regeneration, 2022, 30, 334-337.	3.0	12
15	Surgical Treatment in Hidradenitis Suppurativa. Journal of Clinical Medicine, 2022, 11, 2311.	2.4	10
16	Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. American Journal of Clinical Dermatology, 2022, 23, 615-634.	6.7	63
17	From the Cochrane Library: Interventions for Preventing Occupational Irritant Hand Dermatitis. JMIR Dermatology, 2022, 5, e37961.	0.7	0
18	Synergistic induction of IL-23 by TNFÎ±, IL-17A, and EGF in keratinocytes. Cytokine, 2021, 138, 155357.	3.2	17

#	ARTICLE	IF	CITATIONS
19	Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum. <i>Journal of Investigative Dermatology</i> , 2021, 141, 59-63.	0.7	41
20	Simultaneous endemic pemphigus foliaceus and psoriasis vulgaris in Peru –“ immunogenetic or environmental factors?. <i>Przegląd Dermatologiczny</i> , 2021, 108, 153-159.	0.1	0
21	Treatment of pyoderma gangrenosum: A multicenter survey–based study assessing satisfaction and quality of life. <i>Dermatologic Therapy</i> , 2021, 34, e14736.	1.7	9
22	Gap of knowledge in diagnosis of pyoderma gangrenosum in clinical specialties education. <i>Diagnosis</i> , 2021, 8, 421-424.	1.9	1
23	Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review. <i>Clinical Rheumatology</i> , 2021, 40, 3963-3969.	2.2	10
24	Pyoderma gangrenosum underrepresentation in non-dermatological literature. <i>Diagnosis</i> , 2021, 8, 85-90.	1.9	7
25	From the Cochrane Library: Systemic treatments for eczema, a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	0
26	Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. <i>Journal of Dermatological Treatment</i> , 2020, 31, 723-726.	2.2	10
27	Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 157-161.	3.1	20
28	The utility and challenges of histopathologic evaluation in the diagnosis of nonmalignant skin ulcers. <i>Wound Repair and Regeneration</i> , 2020, 28, 219-223.	3.0	3
29	Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1179-1185.	4.1	16
30	Pyoderma gangrenosum: From historical perspectives to emerging investigations. <i>International Wound Journal</i> , 2020, 17, 1255-1265.	2.9	24
31	Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review*. <i>British Journal of Dermatology</i> , 2020, 183, 821-828.	1.5	12
32	Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1553-1567.	1.2	35
33	Adverse cutaneous reactions to chemotherapeutic drugs. <i>Clinics in Dermatology</i> , 2020, 38, 712-728.	1.6	14
34	A Treatment-Refractory, Perianal Tumor Arising in an Otherwise Healthy Older Adult Woman. <i>JAMA Dermatology</i> , 2020, 156, 453.	4.1	0
35	Perioperative management of pyoderma gangrenosum. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 369-374.	1.2	12
36	International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings. <i>Clinical Rheumatology</i> , 2020, 39, 1839-1850.	2.2	9

#	ARTICLE	IF	CITATIONS
37	Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris. <i>JAMA Dermatology</i> , 2020, 156, 668.	4.1	41
38	Management of Classic Ulcerative Pyoderma Gangrenosum. , 2020, 106, 119-123;E2;E3.		4
39	Successful Mastectomy and Chemotherapy in a Patient with Breast Cancer and Active Generalized Pyoderma Gangrenosum. <i>Wounds</i> , 2020, 32, E19-E22.	0.5	0
40	Biologic and small-molecule medications in the management of pyoderma gangrenosum. <i>Journal of Dermatological Treatment</i> , 2019, 30, 264-276.	2.2	29
41	Pyoderma gangrenosum: a review with special emphasis on Latin America literature. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 729-743.	1.1	13
42	Characterisation and diagnosis of ulcers in inpatient dermatology consultation services: A multi-centre study. <i>International Wound Journal</i> , 2019, 16, 1440-1444.	2.9	8
43	Do I Have Calciphylaxis?. <i>JAMA Dermatology</i> , 2019, 155, 872.	4.1	1
44	Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. <i>Annals of Hematology</i> , 2019, 98, 2247-2248.	1.8	13
45	Primary Immunodeficiency, a Possible Cause of Neutrophilic Necrotizing Dermatitis Reply. <i>JAMA Dermatology</i> , 2019, 155, 864.	4.1	0
46	Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1059.	4.8	92
47	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis ABCD-10. <i>JAMA Dermatology</i> , 2019, 155, 448.	4.1	69
48	Extracutaneous involvement of pyoderma gangrenosum. <i>Archives of Dermatological Research</i> , 2019, 311, 425-434.	1.9	35
49	Insights Into the Pathogenesis of Sweet's Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 414.	4.8	88
50	Sweet syndrome: A glimpse into the pathophysiology. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, AB281.	1.2	0
51	Carcinoma Erysipeloides From Metastatic Cutaneous Squamous Cell Carcinoma Initially Mistaken for Intralymphatic Histiocytosis. <i>American Journal of Dermatopathology</i> , 2019, 41, 522-525.	0.6	3
52	Clinical Features of Neutrophilic Dermatitis Variants Resembling Necrotizing Fasciitis. <i>JAMA Dermatology</i> , 2019, 155, 79.	4.1	37
53	Asociación entre la hidradenitis supurativa y el síndrome metabólico: Revisión sistemática y metaanálisis. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 279-288.	0.4	12
54	White concretions on the hair shaft. <i>Cutis</i> , 2019, 103, E8-E9.	0.3	0

#	ARTICLE	IF	CITATIONS
55	A systematic review of pyoderma gangrenosum with pulmonary involvement: clinical presentation, diagnosis and management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e295-e297.	2.4	11
56	LPIN2 gene mutation in a patient with overlapping neutrophilic disease (pyoderma gangrenosum and) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tr</i>	0.8	11
57	Diversity in dermatology: Roadmap for improvement. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 337-341.	1.2	65
58	Reply to: pyoderma gangrenosum: a clinical conundrum. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e382.	2.4	1
59	Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1195-1204.e1.	1.2	62
60	Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 764-767.e1.	1.2	13
61	Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. <i>British Journal of Dermatology</i> , 2018, 178, e35-e36.	1.5	25
62	Antidesmoglein 1 and 3 antibodies in healthy subjects of a population in the Peruvian high amazon. <i>International Journal of Dermatology</i> , 2018, 57, 344-348.	1.0	1
63	Treatment of an ulcerated hemangioma with dehydrated human amnion/chorion membrane allograft. <i>JAAD Case Reports</i> , 2018, 4, 890-892.	0.8	6
64	Reply to: "Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need". <i>Journal of the American Academy of Dermatology</i> , 2018, 79, e89.	1.2	2
65	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2315-2321.	0.7	94
66	Oxidative stress in patients with endemic pemphigus foliaceus and healthy subjects with anti-desmoglein 1 antibodies. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 212-215.	1.1	2
67	Pyoderma Gangrenosum: What Do We Know Now?. <i>Current Dermatology Reports</i> , 2018, 7, 147-157.	2.1	10
68	Pyoderma Gangrenosum of the Scalp: A Rare Clinical Variant. <i>Wounds</i> , 2018, 30, E16-E20.	0.5	4
69	Update on calciphylaxis etiopathogenesis, diagnosis, and management. <i>Cutis</i> , 2018, 102, 395-400.	0.3	2
70	Somatic symptom disorder in dermatology. <i>Clinics in Dermatology</i> , 2017, 35, 246-251.	1.6	5
71	191 Secukinumab treatment of individuals with psoriasis infected with hepatitis B and/or hepatitis C virus. <i>Journal of Investigative Dermatology</i> , 2017, 137, S32.	0.7	3
72	Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S64-S68.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Incidental skin malignancies in teledermatology and in-person cohorts in the Veterans Affairs Health System. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 965-966.	1.2	11
74	252 Dysregulation of the innate immune system in lesional and non-lesional skin of patients with pyoderma gangrenosum. <i>Journal of Investigative Dermatology</i> , 2017, 137, S43.	0.7	0
75	Ocular pyoderma gangrenosum: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 512-518.	1.2	12
76	Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. <i>British Journal of Dermatology</i> , 2017, 177, 72-83.	1.5	43
77	Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment. <i>British Journal of Dermatology</i> , 2016, 174, 77-87.	1.5	32
78	Scattered targetoid papules and mucosal erosions after vaccination. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e129-e130.	1.2	0
79	Calciphylaxis with evidence of hypercoagulability successfully treated with unfractionated heparin: a multidisciplinary approach. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 275-278.	1.3	8
80	Aortic Endograft and Epithelioid Sarcoma: A Random Association or Causality?. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 897-9.	0.8	3
81	Acute generalized exanthematous pustulosis: atypical presentations and outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 209-214.	2.4	33
82	Pathophysiology of pyoderma gangrenosum (PG): An updated review. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 691-698.	1.2	212
83	Vulvar edema and weight loss in a pediatric patient. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e193-e194.	1.2	0
84	Molecular characterization and antifungal susceptibility of <i>Cryptococcus neoformans</i> strains collected from a single institution in Lima, Peru. <i>Revista Iberoamericana De Micologia</i> , 2015, 32, 88-92.	0.9	9
85	Dapsone and Autoimmune Bullous Disorders. , 2015, , 493-499.		0
86	An Approach to Skin Lesions in the Returning Traveler. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 81-89.	1.9	0
87	A rapidly progressive and fatal case of atypical acute generalized exanthematous pustulosis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e89-e90.	1.2	19
88	Endemic pemphigus foliaceus in the Peruvian Amazon. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 594-600.	1.3	13
89	Microarray Technique, Analysis, and Applications in Dermatology. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1-4.	0.7	21
90	Cutaneous Blastomycosis. <i>New England Journal of Medicine</i> , 2013, 368, e13.	27.0	3

#	ARTICLE	IF	CITATIONS
91	Cutaneous blastomycosis: a clue to a systemic disease. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 287-289.	1.1	16
92	Amlodipine-induced subacute cutaneous lupus. <i>North American Journal of Medical Sciences</i> , 2013, 5, 246.	1.7	4
93	Crusted scabies and multiple dosages of ivermectin. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 584-5.	0.8	13
94	Historical notes on endemic pemphigus in South America. <i>International Journal of Dermatology</i> , 2012, 51, 477-481.	1.0	4
95	Endemic pemphigus in the peruvian Amazon: epidemiology and risk factors for the development of complications during treatment. <i>Anais Brasileiros De Dermatologia</i> , 2012, 87, 838-845.	1.1	16
96	Estudio comparativo del maíz morado ( <i>Zea mays</i> L.) y simvastatina en la reducción de lípidos séricos de pacientes diabéticos normotensos con dislipidemia. <i>Anales De La Facultad De Medicina</i> , 2012, 73, 113.	0.1	5
97	Necrolytic acral erythema. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 1370-1.	0.8	2
98	Update on the characterization of <i>Staphylococcus aureus</i> skin infections in a pediatric dermatology tertiary health care outpatient facility: Antibiotic susceptibility patterns and decreased methicillin resistance. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 440-441.	1.2	9
99	Miliaria-rash after neutropenic fever and induction chemotherapy for acute myelogenous leukemia. <i>Anais Brasileiros De Dermatologia</i> , 2011, 86, 104-106.	1.1	7
100	Aspirin Desensitization/Challenge in 3 Patients With Unstable Angina. <i>American Journal of the Medical Sciences</i> , 2010, 340, 418-420.	1.1	17
101	Night Blindness in a Patient With Acquired Immunodeficiency Syndrome. <i>American Journal of the Medical Sciences</i> , 2010, 339, 457.	1.1	1
102	Skin diseases in the Peruvian Amazonia. <i>International Journal of Dermatology</i> , 2010, 49, 794-800.	1.0	13
103	Facial porokeratosis: A series of six patients. <i>Australasian Journal of Dermatology</i> , 2010, 51, 191-194.	0.7	20
104	Influence of climatic factors on the medical attentions of dermatologic diseases in a hospital of Lima, Peru. <i>Anais Brasileiros De Dermatologia</i> , 2010, 85, 461-468.	1.1	22
105	Cutaneous manifestations of internal malignancies in a tertiary health care hospital of a developing country. <i>Anais Brasileiros De Dermatologia</i> , 2010, 85, 736-742.	1.1	19
106	<i>Cryptococcus gattii</i> meningoencephalitis in an HIV-negative patient from the Peruvian Andes. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2010, 43, 469-471.	0.9	5
107	Characterization of <i>Staphylococcus aureus</i> cutaneous infections in a pediatric dermatology tertiary health care outpatient facility. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 804-811.	1.2	21
108	Cutaneous acanthamebiasis infection in immunocompetent and immunocompromised patients. <i>International Journal of Dermatology</i> , 2009, 48, 1324-1329.	1.0	36

#	ARTICLE	IF	CITATIONS
109	Noninfectious dermatological diseases associated with chronic exposure to mine tailings in a Peruvian district. <i>British Journal of Dermatology</i> , 2008, 159, 169-174.	1.5	8
110	Eosinophilic fasciitis in a female child. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, S72-S74.	1.2	20
111	Multivessel Acute Myocardial Infarction: Case Report and Review of the Literature. <i>American Journal of the Medical Sciences</i> , 2008, 335, 375-378.	1.1	2
112	Endemic Pemphigus Vulgaris. <i>Archives of Dermatology</i> , 2007, 143, 895.	1.4	37
113	Antibodies against desmoglein 1 in healthy subjects in endemic and nonendemic areas of pemphigus foliaceus (fogo selvagem) in Peru. <i>International Journal of Dermatology</i> , 2006, 45, 538-542.	1.0	31